share_log

Raymond James Downgrades Galmed Pharmaceuticals to Market Perform

Benzinga Real-time News ·  May 18, 2022 18:18

Raymond James analyst Steven Seedhouse downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Outperform to Market Perform.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment